<i>MSC1</i> do not support tumor growth whereas <i>MSC2</i> favor tumor growth and metastasis.

<p>The established syngeneic mouse model for epithelial ovarian cancer used is based upon a spontaneously transformed mouse ovarian surface epithelial cell (MOSEC) line ID8 that has been previously described <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0045590#pone.0045590-Roby1" target="_blank">[21]</a>. At approximately 4 weeks a single dose of human MSCs (MSCs), <i>MSC1</i>, or <i>MSC2</i> (1×10⁶/per mouse) were injected intraperitonealy (IP) as indicated by red arrow. <b>A.</b> Tumor growth was measured at weekly intervals until day of mouse sacrifice (Day 65). Harvested tumors and metastasis were weighed, counted and processed for flow cytometry and immunohistochemical analysis (IHC). *<i>P</i><0.05 versus the MSCs-treated tumors. <b>B.</b> Accumulated ascites was collected, measured, and a sample was spun on cytospin slides and stained by DiffQuick cytology stain by standard methods. Left circles are representative micrographs of cytospin slides (20X) with enlarged areas to the right marked by green box (100X). <b>C.</b> Table of average +/−SEM results among the different MSC-treatment groups. Data are representative of three independent experiments with at least 6 mice per treatment group.